TIDMMXCT TIDMTTM
RNS Number : 6275A
MaxCyte, Inc.
23 January 2024
MaxCyte Signs Strategic Platform License with Imugene to Advance
their Cancer Immunotherapy Programs
Imugene using MaxCyte's Flow Electroporation(R) technology and
ExPERT(TM) platform to support azer-cel - a potential
first-in-class allogeneic CD19 CAR T product candidate for the
treatment of blood cancer along with additional novel cell therapy
programs.
ROCKVILLE, MD, and SYDNEY, Australia, Jan. 23, 2024 - MaxCyte,
Inc. , (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering
focused company providing enabling platform technologies to advance
the discovery, development and commercialization of next-generation
cell-based therapeutics and innovative bioprocessing applications,
and Imugene , (ASX: IMU) , a clinical-stage immuno-oncology and
cell therapy company developing a range of new treatments that seek
to activate the immune system of cancer patients to identify and
eradicate tumors, today announced the signing of a strategic
platform license (SPL).
Under the terms of the agreement, Imugene obtains non-exclusive
clinical and commercial rights to use MaxCyte's Flow
Electroporation(R) technology and ExPERT(TM) platform. In return,
MaxCyte is entitled to receive platform licensing fees and
program-related revenue.
Imugene, which has offices in the United States and Australia,
is focused on developing transformative cancer medicines to improve
patients' lives. Its unique technology platforms are designed to
harness and promote the body's immune system against tumors.
Imugene's product pipeline includes an off-the-shelf (allogeneic)
cell therapy CAR T drug called azer-cel (azercabtagene zapreleucel)
that targets CD19 to attack blood cancer, as well as an oncolytic
virus and B-cell immunotherapies aimed at treating a variety of
cancers in combination with standard-of-care medicines and
immunotherapies. Azer-cel is currently being evaluated in an
ongoing multi-center Phase 1b CAR T clinical trial in patients with
non-Hodgkin's lymphoma, a type of blood cancer.
"By leveraging our scalable cell-engineering process and
optimized clinical manufacturing workflow, Imugene is rapidly
moving towards a potential Phase 2 registrational trial for
azer-cel in cancer," said Maher Masoud, President and CEO of
MaxCyte . "Our technology has been integral to the manufacturing of
the allogeneic T-cell immunotherapies and was efficiently
transferred from Precision Biosciences when Imugene obtained global
rights for azer-cel from Precision in August 2023 . With our new
partnership, we will continue to support the development of
azer-cel along with additional novel cell therapy programs."
"Imugene is passionate about bringing effective new treatments
and options to cancer patients," said Leslie Chong, CEO and
Managing Director at Imugene. "We were able to make a seamless
transition from Precision and finalized optimization of our
processes for GMP manufacturing of azer-cel in our state-of-the-art
facility in North Carolina using MaxCyte's technology, giving us
the ability to scale and move forward quickly with this drug
product in the future."
MaxCyte's ExPERT(TM) instrument portfolio is the next generation
of leading, clinically validated electroporation technology for
complex and scalable cell engineering. The ExPERT(TM) platform
delivers the high-end performance essential to enabling the next
wave of biological and cellular therapeutics by providing high
transfection efficiency, seamless scalability and enhanced
functionality. Imugene is MaxCyte's 25(th) SPL overall, which
generates pre-commercial milestone revenue, the vast majority of
which includes post-commercial revenue.
About MaxCyte
At MaxCyte, we pursue cell engineering excellence to maximize
the potential of cells to improve patients' lives. We have spent
more than 20 years honing our expertise by building best-in-class
platforms, perfecting the art of the transfection workflow, and
venturing beyond today's processes to innovate tomorrow's
solutions. Our ExPERT(TM) platform, which is based on our Flow
Electroporation(R) technology, has been designed to support the
rapidly expanding cell therapy market and can be utilized across
the continuum of the high-growth cell therapy sector, from
discovery and development through commercialization of
next-generation, cell-based medicines. The ExPERT family of
products includes: four instruments, the ATx(TM), STx(TM), GTx(TM)
and VLx (TM); a portfolio of proprietary related processing
assemblies or disposables; and software protocols, all supported by
a robust worldwide intellectual property portfolio. By providing
our partners with the right technology, as well as scientific,
technical and regulatory support, we aim to guide them on their
journey to transform human health. Learn more at maxcyte.com and
follow us on X (formerly Twitter) and LinkedIn .
About Imugene
Imugene is a clinical stage immuno-oncology company developing a
range of new and novel immunotherapies that seek to activate the
immune system of cancer patients to treat and eradicate tumors. Our
unique platform technologies seek to harness the body's immune
system against tumors, potentially achieving a similar or greater
effect than synthetically manufactured monoclonal antibody and
other immunotherapies. Our pipeline includes an off-the-shelf
(allogeneic) cell therapy CAR T drug azer-cel (azercabtagene
zapreleucel), which targets CD19 to treat blood cancers. Our
pipeline also includes multiple immunotherapy B-cell vaccine
candidates and an oncolytic virotherapy (CF33) aimed at treating a
variety of cancers in combination with standard of care drugs and
emerging immunotherapies such as CAR Ts for solid tumors. We are
supported by a leading team of international cancer experts with
extensive experience in developing new cancer therapies with many
approved for sale and marketing for global markets.
Our vision is to help transform and improve the treatment of
cancer and the lives of the millions of patients who need effective
treatments. This vision is backed by a growing body of clinical
evidence and peer-reviewed research. Imugene is well funded and
resourced, to deliver on its commercial and clinical milestones.
Together with leading specialists and medical professionals, we
believe Imugene's immuno-oncology therapies will become foundation
treatments for cancer. Our goal is to ensure that Imugene and its
shareholders are at the forefront of this rapidly growing global
market.
MaxCyte Contacts:
US IR Adviser
Gilmartin Group
David Deuchler, CFA
+1 415-937-5400
ir@maxcyte.com
US Media Relations
Spectrum Seismic Collaborative
Valerie Enes
+1 408-497-8568
valerie@spectrumscience.com
Nominated Adviser and Joint Corporate Broker
Panmure Gordon
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden
+44 (0)20 7886 2500
UK IR Adviser
ICR Consilium
Mary-Jane Elliott
Chris Welsh
+44 (0)203 709 5700
maxcyte@consilium-comms.com
Imugene Limited Contacts:
Leslie Chong
Managing Director and Chief Executive Officer
info@imugene.com
Investor Enquiries
shareholderenquiries@imugene.com
Media Enquiries
Matt Wright
matt@nwrcommunications.com.au
Connect with us on LinkedIn @Imugene Limited
Follow us on Twitter @TeamImugene
Watch us on YouTube @ImugeneLimited
Join us on InvestorHub; investorhub.imugene.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
AGRBJMBTMTMTBII
(END) Dow Jones Newswires
January 23, 2024 08:05 ET (13:05 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Apr 2024 to May 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From May 2023 to May 2024